Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03

Ähnliche Einträge

• Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse
  von: Cyrille Touzeau, et al.
  Veröffentlicht: (2025)
• A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience
  von: Anna Furlan, et al.
  Veröffentlicht: (2024)
• Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
  von: Evangelos Terpos, et al.
  Veröffentlicht: (2024)
• Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma
  von: Luca Bettolini, et al.
  Veröffentlicht: (2024)
• A multicentre prospective phase II study of rituximab combined with bortezomib, lenalidomide and dexamethasone, followed by lenalidomide maintenance (R‐ VRD ) in patients with Waldenström's macroglobulinaemia ( KMM1803 )
  von: Sung‐Hoon Jung, et al.
  Veröffentlicht: (2025)